Research Papers:

Probiotic DSF counteracts chemotherapy induced neuropathic pain

Vanessa Castelli, Paola Palumbo, Michele d'Angelo, Nandha Kumar Moorthy, Andrea Antonosante, Mariano Catanesi, Francesca Lombardi, Dalila Iannotta, Benedetta Cinque, Elisabetta Benedetti, Rodolfo Ippoliti, Maria Grazia Cifone and Annamaria Cimini _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:27998-28008. https://doi.org/10.18632/oncotarget.25524

Metrics: PDF 1758 views  |   HTML 2140 views  |   ?  


Vanessa Castelli1, Paola Palumbo1, Michele d'Angelo1, Nandha Kumar Moorthy1, Andrea Antonosante1, Mariano Catanesi1, Francesca Lombardi1, Dalila Iannotta1, Benedetta Cinque1, Elisabetta Benedetti1, Rodolfo Ippoliti1, Maria Grazia Cifone1 and Annamaria Cimini1,2

1Department of Life, Health and Environmental Sciences, University of L’Aquila, L'Aquila, Italy

2Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Temple University, Philadelphia, USA

Correspondence to:

Annamaria Cimini, email: [email protected]

Maria Grazia Cifone, email: [email protected]

Keywords: neuropathic pain; inflammation; IL-8

Received: February 21, 2018     Accepted: May 09, 2018     Published: June 15, 2018


Problem statement: Chemotherapy-induced peripheral neuropathy (CIPN) is a widespread and potentially disabling side effect of various anticancer drugs. In spite of the intensive research focused on obtaining therapies capable to treat or prevent CIPN, the medical demand remains very high. Microtubule-stabilizing agents, among which taxanes, are effective chemotherapeutic agents for the therapy of several oncologic diseases. The inflammatory process activated by chemotherapeutic agents has been interpreted as a potential trigger of the nociceptive process in CIPN. The chemotherapy-driven release of proinflammatory and chemokines has been recognized as one of the principal mechanisms controlling the establishment of CIPN. Several reports have indicated that probiotics are capable to regulate the balance of anti-inflammatory and pro-inflammatory cytokines. Accordingly, it has been suggested that some probiotic formulations, may have an effective role in the management of inflammatory pain symptoms. Experimental approaches used: we tested the hypothesis that paclitaxel-induced neuropathic pain can be counteracted by the probiotic DSF by using an in vitro model of sensitive neuron, the F11 cells. On this model, the biomolecular pathways involved in chemotherapy induced peripheral neuropathy depending on inflammatory cytokines were investigated by Real-time PCR, Western blotting and confocal microscopy. General conclusions: the results obtained, i.e. the increase of acetylated tubulin, the increase of the active forms of proteins involved in the establishment of neuropathic pain, point towards the use of this probiotic formulation as a possible adjuvant agent for counteracting CINP symptoms.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25524